ADC Therapeutics SA (ADCT) stock
ADCTNYSEPharmaceutical PreparationsFiscal year ends December 31
$1.37+0.02 (+1.48%)
Close on Nov 18, 2026Market cap $174.90MP/E –Yield –
ADC Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
ADC Therapeutics's operating income for the twelve months ending Sep 30, 2026 was -$82.93M. For fiscal 2025 it was -$121.50M. The highest annual figure on record is -$119.40M in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$121.50M | – |
| FY2024 | Dec 31, 2024 | -$130.65M | – |
| FY2023 | Dec 31, 2023 | -$165.99M | – |
| FY2022 | Dec 31, 2022 | -$123.34M | – |
| FY2021 | Dec 31, 2021 | -$261.72M | – |
| FY2020 | Dec 31, 2020 | -$219.26M | – |
| FY2019 | Dec 31, 2019 | -$119.40M | – |
| FY2018 | Dec 31, 2018 | -$125.94M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$14.35M | – |
| Q2 FY2026 | Jun 30, 2026 | -$25.41M | – |
| Q1 FY2026 | Mar 31, 2026 | -$25.25M | – |
| Q4 FY2025 | Dec 31, 2025 | -$17.92M | – |
| Q3 FY2025 | Sep 30, 2025 | -$30.97M | – |
| Q2 FY2025 | Jun 30, 2025 | -$44.15M | – |
| Q1 FY2025 | Mar 31, 2025 | -$28.46M | – |
| Q4 FY2024 | Dec 31, 2024 | -$32.44M | – |
| Q3 FY2024 | Sep 30, 2024 | -$35.56M | – |
| Q2 FY2024 | Jun 30, 2024 | -$29.04M | – |
| Q1 FY2024 | Mar 31, 2024 | -$33.61M | – |
| Q4 FY2023 | Dec 31, 2023 | -$39.98M | – |
| Q3 FY2023 | Sep 30, 2023 | -$36.15M | – |
| Q2 FY2023 | Jun 30, 2023 | -$39.65M | – |
| Q1 FY2023 | Mar 31, 2023 | -$50.21M | – |
| Q4 FY2022 | Dec 31, 2022 | -$10.46M | – |
| Q3 FY2022 | Sep 30, 2022 | -$3.11M | – |
| Q2 FY2022 | Jun 30, 2022 | -$69.41M | – |
| Q1 FY2022 | Mar 31, 2022 | -$40.36M | – |
| Q4 FY2021 | Dec 31, 2021 | -$62.78M | – |
| Q3 FY2021 | Sep 30, 2021 | -$57.79M | – |
| Q2 FY2021 | Jun 30, 2021 | -$70.48M | – |
| Q1 FY2021 | Mar 31, 2021 | -$70.67M | – |
| Q4 FY2020 | Dec 31, 2020 | -$78.00M | – |
| Q3 FY2020 | Sep 30, 2020 | -$52.43M | – |
| Q2 FY2020 | Jun 30, 2020 | -$44.95M | – |
| Q1 FY2020 | Mar 31, 2020 | -$43.89M | – |
See a number that looks wrong?